Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines

LONDON, July 17, 2017 /PRNewswire/ —

Get 10% Free Customization in this Report

Adult Vaccines Market is expected to be close to US$ 20 Billion by the year 2022. Because of vaccines, some diseases (like Polio and Diphtheria) are becoming rare. Vaccination can prevent certain deadly diseases in all age groups. Almost all countries around the world have introduced efficient National Immunization Programme in their vaccination schedule to overcome the epidemics caused by vaccine-preventable diseases. WHO’s Global Vaccine Action Plan, Global Immunization Vision and Strategy (GIVS), The GAVI Alliance all are putting their best to minimize the incidence of vaccine-preventable diseases which indeed is driving the adult vaccine market vigorously.

Download the full report: https://www.reportbuyer.com/product/4998222/

Influenza Vaccine Leads the Adult Vaccine Market for the Year 2017

Influenza vaccine is dominating the adult vaccine segment in year 2017, however it will lose its place to Pneumococcal vaccine in the coming future as admissions for pneumonia had almost tripled over the last 15 years. Other than Influenza and Pneumococcal Vaccines, Cervical Cancer (HPV), Hepatitis and Travel vaccines also have considerable market share in adult vaccines market.

Considerable Growth in Immunization of Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV Vaccines

In terms of Immunization; Influenza holds the maximum share as influenza vaccination is recommended to take annually in almost all countries of the world. However, with the growing awareness and efficiency of vaccines in preventing diseases, our analysis found that there will be considerably growth in the number for people opting for Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV vaccines in future till 2022.

Administration of Vaccines Doses

Influenza Vaccine holds the topmost place while talking about the administration of vaccine…

Read the full article from the Source…

Back to Top